Çetin Kürşad akpinar, 1 Nilgün cengiZ

8

Status Epileptikus’un Güncel Tanı, Tedavi ve Etiyolojisi

9

Ketamine for refractory status epilepticus: a case of possible 

ketamine-induced neurotoxicity. Epilepsy Behav 2003;4(1):70-5.

89.  Prüss H, Holtkamp M. Ketamine successfully terminates malig-

nant status epilepticus. Epilepsy Res 2008;82(2-3):219-22. 

90.  Mewasingh LD, Sékhara T, Aeby A, Christiaens FJ, Dan B. Oral 

ketamine in paediatric non-convulsive status epilepticus. Sei-

zure 2003;12(7):483-9.

91.  Martin BS, Kapur J. A combination of ketamine and diazepam 

synergistically controls refractory status epilepticus induced by 

cholinergic stimulation. Epilepsia 2008;49(2):248-55. 

92.  Himmelseher S, Durieux ME. Revising a dogma: ketamine for pa-

tients with neurological injury? Anesth Analg 2005;101(2):524-

34.

93.  Fleischer AC, Cullinan JA, Walsh JW. Problem-oriented gyneco-

logic imaging with emphasis on ultrasonograpy. In: Fleischer 

AC, Manning FA, Jeanty P, Romero R, editors. Sonography in 

obstetrics and gynecology principles and practice. 5th ed. Lon-

don: Appleton and Lange; 1996. p. 887-911.

94.  Breech LL, Rock JA. Uterin leiomyom ve myomektomi. In: Te 

Linde’s Operative Gynecology Türkçe (Turkish translation: 

Tavmergen E). Rock JA, Jones HW (editors), İzmir: Güven Kita-

bevi; 2005. p. 693-730. 

95.  Sapmaz E, Bulgan E. Gosereline and spontaneous myomec-

tomy. Turkiye Klinikleri J Gynecol Obst 2001;11(3):188-90. 

96.  Lhatoo SD, Alexopoulos AV. The surgical treatment of status 

epilepticus. Epilepsia 2007;(48 Suppl 8):61-5.

97.  Patwardhan RV, Dellabadia J Jr, Rashidi M, Grier L, Nanda A. 

Control of refractory status epilepticus precipitated by anticon-

vulsant withdrawal using left vagal nerve stimulation: a case 

report. Surg Neurol 2005;64(2):170-3.

98.  Winston KR, Levisohn P, Miller BR, Freeman J. Vagal nerve stimu-

lation for status epilepticus. Pediatr Neurosurg. 2001;34(4):190-

2.

99.  Holtkamp M, Matzen J, van Landeghem F, Buchheim K, Mei-

erkord H. Transient loss of inhibition precedes spontaneous 

seizures after experimental status epilepticus. Neurobiol Dis 

2005;19(1-2):162-70.

100. Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, et 

al. A comparison of lorazepam, diazepam, and placebo for the 

treatment of out-of-hospital status epilepticus. N Engl J Med 

2001;345(9):631-7.

101. Claassen J, Lokin JK, Fitzsimmons BF, Mendelsohn FA, Mayer 

SA. Predictors of functional disability and mortality after status 

epilepticus. Neurology 2002;58(1):139-42.

102. Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB. Prognosis 

of status epilepticus: role of aetiology, age, and consciousness 

impairment at presentation. J Neurol Neurosurg Psychiatry 

2006;77(5):611-5.

103. Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser 

WA. Time trends in incidence, mortality, and case-fatality after 

first episode of status epilepticus. Epilepsia 2001;42(8):1031-5.

104. Young GB, Jordan KG, Doig GS. An assessment of nonconvul-

sive seizures in the intensive care unit using continuous EEG 

et al. Levetiracetam intravenous infusion: a randomized, pla-

cebo-controlled safety and pharmacokinetic study. Epilepsia 

2006;47(7):1128-35.

73.  Farooq MU, Naravetla B, Majid A, Gupta R, Pysh JJ, Kassab MY. 

IV levetiracetam in the management of non-convulsive status 

epilepticus. Neurocrit Care 2007;7(1):36-9.

74.  Rossetti AO, Bromfield EB. Levetiracetam in the treatment of 

status epilepticus in adults: a study of 13 episodes. Eur Neurol 

2005;54(1):34-8. 

75.  Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo 

RJ. The use of topiramate in refractory status epilepticus. Neu-

rology 2003;60(2):332-4.

76.  Hottinger A, Sutter R, Marsch S, Rüegg S. Topiramate as an 

adjunctive treatment in patients with refractory status epi-

lepticus: an observational cohort study. CNS Drugs 2012 Sep 

1;26(9):761-72. 

77.  Legros B, Depondt C, Levy-Nogueira M, Ligot N, Mavroudakis 

N, Naeije G, et al. Intravenous Lacosamide in Refractory Seizure 

Clusters and Status Epilepticus: Comparison of 200 and 400 mg 

Loading Doses. Neurocrit Care 2013 Jul 30. 

78.  Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of re-

fractory status epilepticus with pentobarbital, propofol, or 

midazolam: a systematic review. Epilepsia 2002;43(2):146-53.

79.  Holtkamp M, Masuhr F, Harms L, Einhäupl KM, Meierkord H, Bu-

chheim K. The management of refractory generalised convul-

sive and complex partial status epilepticus in three European 

countries: a survey among epileptologists and critical care neu-

rologists. J Neurol Neurosurg Psychiatry 2003;74(8):1095-9.

80. Kaplan PW. Nonconvulsive status epilepticus. Neurology 

2003;61(8):1035-6.

81.  Krishnamurthy KB, Drislane FW. Depth of EEG suppression and 

outcome in barbiturate anesthetic treatment for refractory sta-

tus epilepticus. Epilepsia 1999;40(6):759-62.

82.  Hara M, Kai Y, Ikemoto Y. Propofol activates GABAA receptor-

chloride ionophore complex in dissociated hippocampal pyra-

midal neurons of the rat. Anesthesiology 1993;79(4):781-8.

83.  Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and mid-

azolam in the treatment of refractory status epilepticus. Epilep-

sia 2001;42(3):380-6.

84. Rossetti AO, Reichhart MD, Schaller MD, Despland PA, Bo-

gousslavsky J. Propofol treatment of refractory status epilepti-

cus: a study of 31 episodes. Epilepsia 2004;45(7):757-63.

85.  Rossetti AO, Logroscino G, Bromfield EB. Refractory status epi-

lepticus: effect of treatment aggressiveness on prognosis. Arch 

Neurol 2005;62(11):1698-702.

86.  Abend NS, Dlugos DJ. Treatment of refractory status epilepti-

cus: literature review and a proposed protocol. Pediatr Neurol 

2008;38(6):377-90. 

87.  Shibuta S, Varathan S, Mashimo T. Ketamine and thiopental 

sodium: individual and combined neuroprotective effects on 

cortical cultures exposed to NMDA or nitric oxide. Br J Anaesth 

2006;97(4):517-24. 

88.  Ubogu EE, Sagar SM, Lerner AJ, Maddux BN, Suarez JI, Werz MA. 

monitoring: an investigation of variables associated with mor-

tality. Neurology 1996;47(1):83-9.

105. Shneker BF, Fountain NB. Assessment of acute morbidity and 

mortality in nonconvulsive status epilepticus. Neurology 

2003;61(8):1066-73.

106. Wasterlain CG, Fujikawa DG, Penix L, Sankar R. Pathophysiologi-

cal mechanisms of brain damage from status epilepticus. Epi-

lepsia 1993;34 Suppl 1:S37-53.

107. Claassen J, Hirsch LJ, Emerson RG, Bates JE, Thompson TB, 

Mayer SA. Continuous EEG monitoring and midazolam infu-

sion for refractory nonconvulsive status epilepticus. Neurology 

2001;57(6):1036-42.

108. Drislane FW, Blum AS, Lopez MR, Gautam S, Schomer DL. Dura-

tion of refractory status epilepticus and outcome: loss of prog-

nostic utility after several hours. Epilepsia 2009;50(6):1566-71. 

109. Litt B, Wityk RJ, Hertz SH, Mullen PD, Weiss H, Ryan DD, et al. 

Nonconvulsive status epilepticus in the critically ill elderly. Epi-

lepsia 1998;39(11):1194-202.

110. Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of 

mortality in status epilepticus. Epilepsia 1994;35(1):27-34.

111. Bassin S, Smith TL, Bleck TP. Clinical review: status epilepticus. 

Crit Care 2002;6(2):137-42.

Epilepsi 2014;20(1):1-10

10